| 货号 | HCA249 |
| 克隆号 | AbD21375_hIgG1 |
| 同种亚型 | IgG1 |
| 来源宿主 | HuCAL |
| 应用 | E |
| 供应商 | Bio-Rad Antibodies |
| 运输条件 | |
| 存放说明 | Store at -70oC. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.Store at +4oC or at -20oC if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
Human anti natalizumab specificity ELISA A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated Human anti natalizumab (clone AbD21375_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) followed by QuantaBlu™ fluorogenic peroxidase substrate | |
Human anti natalizumab specificity titration ELISA A microtiter plate was coated over night with natalizumab, human IgG4/kappa or human IgG1/kappa at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated Human anti natalizumab (clone AbD21375_hIgG1) titrated to the given concentrations in PBST, followed by QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements | |
Natalizumab bridging ELISA for Pharmacokinetic (PK) assay development A microtiter plate was coated over night with Human anti natalizumab (clone AbD21375, HCA248) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of natalizumab. Detection was performed using HRP-conjugated Human anti natalizumab (clone AbD21375_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements | |
Human anti natalizumab bridging ELISA for Anti-Drug Antibody (ADA) assay development A microtitre plate was coated over night with natalizumab at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of Human anti natalizumab, clone AbD21375_hIgG1 (HCA249) or clone AbD21384_hIgG1 (HCA250). Detection was performed using HRP-conjugated natalizumab. HRP-conjugation of natalizumab used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®. Data is presented as the mean of three measurements | |
Human anti natalizumab inhibits the binding of natalizumab to alpha-4/beta-1 integrin A microtiter plate was coated over night with alpha-4/beta-1 integrin at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, a pre-incubated mixture of natalizumab (0.3 μg/ml) plus increasing concentrations of Human anti natalizumab in its monovalent Fab format was added (clone AbD21375, HCA248). Free natalizumab, still capable of binding to the alpha-4/beta-1 integrin coated plate, was detected using Mouse anti Human IgG (Fc) CH2 domain:HRP (MCA647P) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements |
